Dottikon Es Holding AG
SIX:DESN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
210.5
267
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dottikon Es Holding AG
Dottikon Es Holding AG
Total Equity
Dottikon Es Holding AG
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dottikon Es Holding AG
SIX:DESN
|
Total Equity
CHf917.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
19%
|
CAGR 10-Years
13%
|
|
|
Sika AG
F:SIKA
|
Total Equity
CHf5.9B
|
CAGR 3-Years
22%
|
CAGR 5-Years
29%
|
CAGR 10-Years
11%
|
|
|
C
|
Clariant AG
SIX:CLN
|
Total Equity
CHf2.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Givaudan SA
SIX:GIVN
|
Total Equity
CHf4.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Ems Chemie Holding AG
SIX:EMSN
|
Total Equity
CHf2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
D
|
DSM-Firmenich AG
AEX:DSFIR
|
Total Equity
€22.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Dottikon Es Holding AG
Glance View
Dottikon Es Holding AG stands as one of Switzerland's understated gems in the realm of fine chemicals and pharmaceuticals. Born from Switzerland's rich tradition of precision and quality, the company operates primarily in the realm of exclusive synthesis, tailored to meet the stringent demands of the pharmaceuticals industry. At its core, Dottikon specializes in hazardous chemical reactions, priding itself on an ability to transform complex chemical processes into high-quality results. This specialization provides a competitive edge, allowing Dottikon to focus on developing innovative and complex molecules which serve as active pharmaceutical ingredients (APIs). It's a business model that not only underscores the company's technical expertise but also its commitment to safety and environmental stewardship, given the heightened risks associated with hazardous materials. Revenue for Dottikon is chiefly generated from strategic partnerships with major pharmaceutical companies. By offering a unique combination of research and development capabilities coupled with state-of-the-art production facilities, Dottikon caters to bespoke needs, from initial developmental scales to full-fledged commercial production runs. The trust and collaboration between Dottikon and its clients are pivotal, as the company becomes an indispensable partner in the clients’ supply chain. As the pharmaceutical sector continues to evolve and demand for specialized molecules increases, Dottikon’s focus on exclusivity and expertise positions it well within the industry, ensuring steady demand and solidifying its role as a reliable, albeit lesser-known, catalyst in advancing pharmaceutical innovations.
See Also
What is Dottikon Es Holding AG's Total Equity?
Total Equity
917.9m
CHF
Based on the financial report for Sep 30, 2024, Dottikon Es Holding AG's Total Equity amounts to 917.9m CHF.
What is Dottikon Es Holding AG's Total Equity growth rate?
Total Equity CAGR 10Y
13%
Over the last year, the Total Equity growth was 9%. The average annual Total Equity growth rates for Dottikon Es Holding AG have been 11% over the past three years , 19% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
